Duke logo

ECOG-ACRIN EA5142- Non-Small Cell Lung Cancers - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if adding the study drug Nivolumab will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.

What is the Condition Being Studied?

Non-Small Cell Lung Cancer

Who Can Participate in the Study?

Adults with non-small cell lung cancer who:
- Completed surgical resection of non-small cell lung cancer
- Are not pregnant or nursing
- Do not have an autoimmune disease

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be randomized (Like the flip of a coin) to get either:
-- Group 1: The study drug Nivolumab through an IV in your vein once every 4 weeks for up to 1 year
-- Group 2: Observation with the standard postoperative follow-up
- Have follow-up visits every 3 months for the first two years, every 6 months for the net two years, and then once a year for up to ten years from when you began the study
- Have CT scans of the chest every 6 months until you are 4 years from when you started the study and then every 12 months for up to 10 years from the time you started the study

Study Details

Full Title
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00073268
NCT:NCT02595944
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698